Key PointsThe median overall survival, disease‐free survival and survival from disease progression of patients with progressive disease were 15, 8 months and 5 months, respectively.Twenty‐two (96%) of 23 individuals suffering from disease progression died of the disease. The overall mortality rate was 70%.Patients with progressive MCC spend significantly more tumour‐related days in the hospital compared to patients without a progressive disease.The rate of immunosuppression was significantly higher in the MCC progressive group and those patients received more often radio‐ and/or chemotherapy.Despite an aggressive therapy approach and long hospitalisation, survival among patients suffering from progressive MCC was very poor. Randomised clinical trials are required to assess whether aggressive systemic and local therapy is justified in Merkel cell carcinoma patients with progressive disease.INTRODUCTIONMerkel cell carcinoma is an aggressive and fast‐growing neuroendocrine tumour of the skin. It occurs predominantly on sun‐exposed skin of elderly and/or immunosuppressed people.Approximately 4% of all patients with Merkel cell carcinoma initially present with distant metastases, a stage, where palliative treatment is usually considered. Very limited data are available on palliative treatment in patients suffering from Merkel cell carcinoma. A multimodal radio/chemotherapy concept is advisable for patients suffering from an advanced tumour stage or patients who are not
Clinical Otolaryngology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera